SLC5A2 and hydrops fetalis: Subsequently, large-scale cohort trials such as DAPA-HF, EMPEROR-Reduced, and EMPEROR-Preserved revealed that the cardiovascular benefits of SGLT2 inhibitors are independent of glycemic control, significantly reducing the risk of hospitalization for HF, out-of-hospital worsening, and improving prognosis (Zannad et al., 2020; Packer et al., 2021) (Anker et al., 2021).